These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 7749407

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
    Girault D, Le Deist F, Debré M, Pérignon JL, Herbelin C, Griscelli C, Sciudery D, Hershfield M, Fischer A.
    Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
    [Abstract] [Full Text] [Related]

  • 5. Management options: SCIDS with adenosine deaminase deficiency.
    Hilman BC, Sorensen RU.
    Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB.
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM, Weinberg KI, Kohn DB.
    Med Wieku Rozwoj; 2003 Nov; 7(1):27-34. PubMed ID: 13130167
    [Abstract] [Full Text] [Related]

  • 9. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS.
    Immunodeficiency; 1993 Nov; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS.
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN, Flotte TR.
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM, Culver KW, Chang L, Anderson WF, Mullen C, Nienhuis A, Carter C, Dunbar C, Leitman S, Berger M.
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM, Hershfield MS, Bahna SL.
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [Abstract] [Full Text] [Related]

  • 17. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
    Hoogerbrugge PM, Vossen JM, v Beusechem VW, Valerio D.
    Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
    [No Abstract] [Full Text] [Related]

  • 18. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
    Booth C, Hershfield M, Notarangelo L, Buckley R, Hoenig M, Mahlaoui N, Cavazzana-Calvo M, Aiuti A, Gaspar HB.
    Clin Immunol; 2007 May; 123(2):139-47. PubMed ID: 17300989
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency.
    Fairbanks LD, Simmonds HA, Hoogerbrugge PM, van Beusechem VW, Valerio D, Moseley A, Levinsky RJ, Gaspar HB, Morgan G.
    Adv Exp Med Biol; 1994 May; 370():391-4. PubMed ID: 7660936
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.